Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/27142
Title: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)
Authors: Hagop Kantarjian
Ricardo Pasquini
Vincent Lévy
Saengsuree Jootar
Jerzy Holowiecki
Nelson Hamerschlak
Timothy Hughes
Eric Bleickardt
David Dejardin
Jorge Cortes
Neil P. Shah
University of Texas MD Anderson Cancer Center
Hospital de Clínicas de Curitiba
Hopital Saint-Louis
Mahidol University
University Hospital-SPSKM
Hospital Israelita Albert Einstein
Institute of Medical and Veterinary Science Australia
Bristol-Myers Squibb
UCSF School of Medicine
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 15-Sep-2009
Citation: Cancer. Vol.115, No.18 (2009), 4136-4147
Abstract: BACKGROUND: In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325-fold more potent inhibition than imatinib against unmutated Bcr-Abl in vitro. Data with a minimum of 2 years of follow-up were available for the current study of dasatinib and high-dose imatinib in CP-CML resistant to imatinib at daily doses from 400 mg to 600 mg. METHODS: A phase 2, open-label study was initiated of 150 patients with imatinib-resistant CP-CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n = 101) or high-dose imatinib 800 mg (400 mg twice daily; n = 49). RESULTS: At a minimum follow-up of 2 years, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%; P = .034), major cytogenetic response (MCyR) (53% vs 33%; P = .017), and complete cytogenetic response (44% vs 18%; P = .0025). At 18 months, the MCyR was maintained in 90% of patients on the dasatinib arm and in 74% of patients on the high-dose imatinib arm. Major molecular response rates also were more frequent with dasatinib than with high-dose imatinib (29% vs 12%; P = .028). The estimated progression-free survival also favored dasatinib (unstratified log-rank test; P = .0012). CONCLUSIONS: After 2 years of follow-up, dasatinib demonstrated durable responses and improved response and progressionfree survival rates relative to high-dose imatinib. © 2009 American Cancer Society.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=70149105272&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/27142
ISSN: 10970142
0008543X
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.